SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Mutation A227G

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Potential Association of a Common L-FABP Polymorphism With Lipid-induced Hepatic Insulin Resistance

The investigators hypothesise that a common A277G polymorphism of the liver fatty acid binding protein (L-FABP) gene, which leads to an amino acid exchange, may be associated with alterations of lipid-induced hepatic insulin resistance. In the present study the investigators will investigate potential differences in lipid-induced hepatic insulin resistance, and in the relation between glycogenolysis and gluconeogenesis, in healthy subjects with the A277G polymorphism vs. subjects carrying the wildtype.

NCT00277342 Wildtype Polymorphism Liver FABP Procedure: measurement of lipid-induced hepatic insulin resistance
MeSH:Insulin Resistance
HPO:Insulin resistance

Only one common non-synonymous polymorphism (A227G) leading to an amino-acid exchange in the exonic region of the L-FABP gene has been previously identified. --- A227G ---

Primary Outcomes

Measure: lipid-induced hepatic insulin resistance(WT vs.SNP L-FABP)

Measure: changes in the relation GNG to GL

Secondary Outcomes

Measure: changes in peripheral plasma glucose and lipid responses

HPO Nodes